Matthew Paul Kowalsky - Feb 28, 2023 Form 3 Insider Report for Sigilon Therapeutics, Inc. (SGTX)

Role
CHIEF OF STAFF AND CLO
Signature
/s/ Matthew Kowalsky
Stock symbol
SGTX
Transactions as of
Feb 28, 2023
Transactions value $
$0
Form type
3
Date filed
3/1/2023, 03:35 PM
Next filing
Aug 11, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SGTX Common Stock 19.7K Feb 28, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SGTX Stock Option (Right to Buy) Feb 28, 2023 Common Stock 77.8K $4.12 Direct F2
holding SGTX Stock Option (Right to Buy) Feb 28, 2023 Common Stock 1.11K $9.39 Direct F3
holding SGTX Stock Option (Right to Buy) Feb 28, 2023 Common Stock 50K $39.81 Direct F4
holding SGTX Stock Option (Right to Buy) Feb 28, 2023 Common Stock 90K $3.03 Direct F5
holding SGTX Stock Option (Right to Buy) Feb 28, 2023 Common Stock 105K $1.48 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 10,000 restricted stock units that vest as to 25% on October 29, 2023, which is the second anniversary of the date of grant, and 75% on the third anniversary of the date of grant, subject to the grantee's continued service to the Company on each vesting date.
F2 The option vested as to 25% of the underlying shares of common stock on May 6, 2020, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.
F3 The option vested as to 50% of the underlying shares of common stock on October 23, 2020, based on the Company's satisfaction of certain performance criteria. The option vested as to 50% of the underlying shares of common stock on October 23, 2021, the first anniversary of the vesting commencement date.
F4 The option vested as to 25% of the underlying shares of common stock on February 11, 2022, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.
F5 The option vested as to 30% of the underlying shares of common stock on January 3, 2023, the first anniversary of the vesting commencement date, and 70% on January 3, 2024.
F6 The option vested as to 25% of the underlying shares of common stock on February 18, 2023, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.